Spontaneous Coronary Artery Dissection National Swiss Registry (SwissSCAD)

Dr. Sophie Degrauwe

Status: Enrolling

Conditions: Spontaneous Coronary Artery Dissection

Study type: Observational

Funder types: Other

Identifiers

NCT04457544

2019-01886

Details and patient eligibility

About

Spontaneous coronary artery dissection (SCAD), is an underdiagnosed pathology, affecting predominantly young women without traditional cardiovascular risk factors and is associated with major adverse outcomes including myocardial infarction, cardiac arrest, or death.

Timely diagnosis of SCAD as well as clinical follow-up are of the essence in this pathology associated with major cardiac adverse outcomes. Despite recent improvements in diagnosis and recognition of the importance of SCAD, it remains poorly studied and understood.

In this context, we designed the SwissSCAD registry, a large, observational, prospective, cohort study, to describe the natural history of SCAD, its outcomes and its treatments.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject is ≥18 years of age.
• Patient presenting newly diagnosed SCAD or diagnosed with SCAD within the last 5 years.
• Subject must be willing to sign a Patient Informed Consent (PIC).

Exclusion criteria

• Patient unwilling or unable to provide informed consent.
• Patients with atherosclerotic or iatrogenic coronary dissection.

Trial design

1,000 participants in 2 patient groups

Retrospective patients

Description:

The investigators will review the hospital records at the investigational site for SCAD events having occurred over the last 5 years. All SCAD patients aged ≥18 years, not presenting atherosclerotic or iatrogenic coronary dissection will be informed about the SwissSCAD study by phone and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the retrospective arm.

Prospective patients

Description:

Patients presenting at the hospital with newly diagnosed SCAD will be informed of the SwissSCAD study and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the prospective arm.